2015 Announcements

December 21, 2015

Holiday Closures

Operations Offices and SDMC Offices: Read more
NRG Oncology Biospecimen Banks: Read more

December 8, 2015

Referral of Patients with pleuropulmonary blastoma (PPB) and PPB-associated tumors (cystic nephroma, Sertoli-Leydig cell tumors and other sex dord-stromal tumors)

The National Cancer Institute’s Clinical Genetics Branch is conducting a study investigating pleuropulmonary blastoma (PPB) and DICER1-associated tumors, including cystic nephroma, Sertoli-Leydig cell tumor and other sex cord-stromal tumors. This study seeks to characterize PPB and other DICER1-associated tumors and to develop evidence-based management guidelines for cancer prevention and riskreduction strategies for patients and their family members. I am writing to you to request your assistance in recruiting patients and their families to this important study. Read more


December 7, 2015

Dr. Wolmark to present award lecture at 2015 San Antonio Breast Cancer Symposium

Norman Wolmark, MD will present the William L. McGuire Memorial Lecture, “The Contribution of NSABP Clinical Trials to the Management of Early Breast Cancer,” on December 9, 2015, at the annual meeting of the San Antonio Breast Cancer Conference. Read more.

December 3, 2015

The AMG 232 Project Team Member Application (PTMA) is a part of the new CTEP ETCTN process and will be studying AMG 232, a potent, selective, orally (PO) available, piperidinone small molecule inhibitor, that can inhibit the interaction between the tumor suppressor protein p53 and the human homolog of murine double minute 2 (Mdm2) (Rew and Sun, 2014; Sun et al., 2014).  

The last day to submit an application to NRG Oncology is December 22, 2015 at 5 PM (ET).

Access Application Materials

June 22, 2015

President Obama Appoints NRG Oncology Researcher Deborah Watkins-Bruner, RN, PhD to the National Cancer Advisory Board

President Barack Obama announced his intention to appoint Deborah Watkins-Bruner, RN, PhD, the NRG Oncology Deputy Chair for Scientific Publications and the contact principal investigator for the NRG Oncology NCORP program, to serve on the National Cancer Advisory Board (NCAB). The board members advise and assist the NCI Director on the activities of the National Cancer Program, including the review of grants and cooperative agreements for research and training. Of the five new NCAB appointees announced last week, President Obama said, “I am honored that these talented individuals have decided to serve our country.  They bring their years of experience and expertise to this Administration, and I look forward to working with them.” Watkins-Bruner is the Robert W. Woodruff Professor of Nursing at the Nell Hodgson Woodruff School of Nursing, Professor of Radiation Oncology, and Associate Director for Outcomes Research at the Winship Cancer Institute of Emory University. “NRG Oncology is  delighted that President Obama has recognized Dr. Bruner’s abilities and the contributions she will make to the NCAB. The NCAB has significant influence in guiding the nation’s strategies against cancer, and Deb will be an invaluable advisor to President Obama and other national leaders on our research policies,” says Walter J. Curran, Jr, MD, an NRG Oncology Group Chairman and Executive Director of the Winship Cancer Institute of Emory University in Atlanta.
Before joining Emory University, Watkins-Bruner served at the University of Pennsylvania as Professor of Nursing and Radiation Oncology from 2006 to 2011 and as co-Leader of the Cancer Prevention and Control Program at the Abramson Cancer Center from 2008 to 2011.  From 1989 to 2006, she held various positions at the Fox Chase Cancer Center, including Nurse Manager/Clinical Specialist in the Department of Radiation Oncology, Director of the Prostate Cancer Risk Assessment Program, and Director of the Symptoms and Outcomes Research Program.  From 1986 to 1989, Watkins-Bruner was a Gyn-Oncology Clinical Nurse Specialist/Program Coordinator at the Albert Einstein Medical Center.  She served as Research Nurse for Burns and Trauma at Crozer-Chester Medical Center from 1985 to 1986.  Watkins-Bruner began her career as a staff nurse at the Crozer-Chester Medical Center from 1978 to 1985 and received a B.S.N. from West Chester University, an M.S.N. in Oncology and an M.S.N. in Administration from Widener University, and a Ph.D. from the University of Pennsylvania. 

May 15, 2015

NIH Biosketch Format Changes Effective May 25, 2015

NIH has released a new Biosketch format (incorporating several major changes) required for all NIH and AHRQ grant applications submitted for due dates on or after May 25, 2015.  Click here for more information.

Fulbright U.S. Scholar Program Award Opportunity

The 2016-2017 Fulbright U.S. Scholar Program to take place in Brussels, Belgium is open to postdoctoral researchers interested in spending 12 months at the European Organization for Research and Treatment of Cancer (EORTC). The selected candidate will receive training in the methodology of cancer clinical and translational research using data from EORTC databases. 

This award is open to medical doctors, statisticians, or translational research scientists interested in entering clinical research. Applicants must be U.S. citizens. The deadline for applications is August 3, 2015. Click here for more information.

February 2015

Bernard Fisher, MD, former chairman of the NSABP, interviewed for Ken Burns special, Cancer: The Emperor of All Maladies
On March 30-April 1, 2015, PBS stations will air a Ken Burns series Cancer: The Emperor of All Maladies based on Siddhartha Mukherjee's book.  Bernard Fisher, MD, a founding member and former chairperson of the NSABP, was interviewed for this production. He will appear in the program’s second episode.   This three-part, six-hour documentary was directed by award-winning filmmaker Barak Goodman and executive produced by Ken Burns. For further information about the series, go to: http://cancerfilms.org/about-the-film/

Press Release from Stand Up to Cancer

January 2015

NSABP B-31/NCCTG N9831 article
The article "Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer: Planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831," from a joint study by the NSABP (NRG Oncology) and NCCTG (Alliance), was announced by ASCO as one of the top 8 articles downloaded from the Journal of Clinical Oncology's website in 2014.  Read the abstract here.

January 2015

Carol Geiger, RN, recipient of the 2014 Joan K. Mauer Memorial Quality Assurance Award
Congratulations to Carol Geiger, RN, who was selected to receive the Joan K. Mauer Memorial Quality Assurance Award for Excellence in Clinical Trial Audits and Quality Assurance.  Ms. Geiger was the 2014 recipient of the Non-Physician award.  Retired from the Central Illinois CCOP, she received the award in recognition of her exceptional dedication as a volunteer auditor for NRG Oncology. 

Ms. Geiger has participated in the NSABP (now NRG Oncology) site visit audit program as a volunteer auditor for over 19 years.  Her first audit was on March 1, 1995, for the NSABP Breast Cancer Prevention Trial (BCPT, P-1), in Milwaukee, Wisconsin.  Since that day, she has participated in over 395 treatment and prevention trial network audits.  Mimi Passarello from the NRG Oncology Statistics and Data Management Center, Pittsburgh office submitted the nomination. Gary L. Smith, Chief, Clinical Trials Monitoring Branch at CTEP said that all of the nominees were highly qualified, but Ms. Geiger's "dedication to ensuring the conduct of high quality clinical trials was particularly commendable."  The award announcement is on the CTEP website at:  http://ctep.cancer.gov/branches/ctmb/mauer.htm




Stay current with science. Sign up for our newsletter.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.